Adamantane derivatives as inhibitors of focal adhesion kinase

USPTO granted patent US12590070B2 to Samjin Pharmaceutical Co., Ltd. on March 31, 2026. The patent covers adamantane derivatives as inhibitors of focal adhesion kinase (FAK), with 17 allowed claims encompassing the compounds, their pharmaceutically acceptable salts, stereoisomers, hydrates, solvates, and pharmaceutical compositions comprising same. The invention is directed toward cancer treatment applications as indicated by CPC classification A61P 35/00. The patent application was originally filed on December 2, 2020, under application number 17782117.\n\nPharmaceutical companies developing FAK inhibitors or cancer therapeutics should review this patent to assess potential licensing needs or freedom-to-operate considerations. Competitors in the adamantane derivatives space should evaluate whether their compounds fall within the scope of the granted claims. The patent provides enforceable exclusivity rights for the standard 20-year term from the filing date.